This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Eastell R (1998) Treatment of postmenopausal osteoporosis. N Engl J Med 338: 736–746
Bone HG et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199
Tashjian AH Jr et al. (2006) Teriparatide [human PTH (1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21: 354–365
Boyle WJ et al. (2003) Osteoclast differentiation and activation. Nature 423: 337–342
Kostenuik PJ (2005) Osteoprotegrin and RANKL regulate bone resorption, density, geometry, and strength. Curr Opin Pharmacol 5: 618–625
Acknowledgements
The synopsis was written by Marie Lofthouse, Assistant Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Favus, M. Does denosumab improve low BMD in postmenopausal women?. Nat Rev Endocrinol 2, 600–601 (2006). https://doi.org/10.1038/ncpendmet0328
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0328
This article is cited by
-
Is denosumab a safe and effective treatment for postmenopausal osteoporosis?
Nature Clinical Practice Endocrinology & Metabolism (2008)